$EHC
Encompass Health Corp Stock $ehc

$ehc Overview Financials Valuation SEC Filings Company Website

2014 Q2 Form 10-Q Financial Statement

#000078516114000043 Filed on July 29, 2014

Income Statement

Concept	2014 Q2	2013 Q2
Revenue	$604.4M	$564.5M
YoY Change	7.07%	5.83%
Cost Of Revenue	$27.80M	$26.60M
YoY Change	4.51%	2.7%
Gross Profit	$567.3M	$530.9M
YoY Change	6.86%	5.97%
Gross Profit Margin	93.86%	94.05%
Selling, General & Admin	$327.8M	$317.2M
YoY Change	3.34%	4.62%
% of Gross Profit	57.78%	59.75%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$26.40M	$23.10M
YoY Change	14.29%	15.5%
% of Gross Profit	4.65%	4.35%
Operating Expenses	$439.7M	$419.3M
YoY Change	4.87%	5.46%
Operating Profit	$127.6M	$111.6M
YoY Change	14.34%	7.93%
Interest Expense	-$25.20M	-$21.10M
YoY Change	19.43%	6.03%
% of Operating Profit	-19.75%	-18.91%
Other Income/Expense, Net	$28.20M	$1.900M
YoY Change	1384.21%	375.0%
Pretax Income	$130.6M	$92.40M
YoY Change	41.34%	10.92%
Income Tax	$36.50M	-$86.50M
% Of Pretax Income	27.95%	-93.61%
Net Earnings	$83.10M	$165.2M
YoY Change	-49.7%	253.75%
Net Earnings / Revenue	13.75%	29.26%
Basic Earnings Per Share	$0.93	$1.82
Diluted Earnings Per Share	$0.85	$1.66
COMMON SHARES
Basic Shares Outstanding	86.70M shares	86.10M shares
Diluted Shares Outstanding	100.6M shares	99.80M shares

Balance Sheet

Concept	2014 Q2	2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$65.80M	$68.70M
YoY Change	-4.22%	67.15%
Cash & Equivalents	$65.80M	$68.70M
Short-Term Investments
Other Short-Term Assets	$103.9M	$111.6M
YoY Change	-6.9%	-18.95%
Inventory
Prepaid Expenses
Receivables	$272.3M	$273.7M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$580.9M	$591.5M
YoY Change	-1.79%	39.34%
LONG-TERM ASSETS
Property, Plant & Equipment	$976.5M	$793.3M
YoY Change	23.09%	10.35%
Goodwill	$34.80M	$13.70M
YoY Change	154.01%	-96.75%
Intangibles	$103.3M	$86.80M
YoY Change	19.01%	25.8%
Long-Term Investments
YoY Change
Other Assets	$148.0M	$138.1M
YoY Change	7.17%	7.22%
Total Long-Term Assets	$1.996B	$1.920B
YoY Change	3.93%	1.53%
TOTAL ASSETS
Total Short-Term Assets	$580.9M	$591.5M
Total Long-Term Assets	$1.996B	$1.920B
Total Assets	$2.577B	$2.512B
YoY Change	2.58%	8.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$55.70M	$57.30M
YoY Change	-2.79%	-3.86%
Accrued Expenses	$243.6M	$254.3M
YoY Change	-4.21%	-4.04%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$299.3M	$311.6M
YoY Change	-3.95%	-4.0%
LONG-TERM LIABILITIES
Long-Term Debt	$1.475B	$1.320B
YoY Change	11.78%	8.23%
Other Long-Term Liabilities	$141.1M	$131.4M
YoY Change	7.38%	-3.24%
Total Long-Term Liabilities	$141.1M	$131.4M
YoY Change	7.38%	-90.3%
TOTAL LIABILITIES
Total Short-Term Liabilities	$299.3M	$311.6M
Total Long-Term Liabilities	$141.1M	$131.4M
Total Liabilities	$1.916B	$1.763B
YoY Change	8.67%	4.94%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.971B	-$2.208B
YoY Change	-10.73%
Common Stock	$1.000M	$1.000M
YoY Change	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$457.6M	$404.0M
YoY Change	13.27%
Treasury Stock Shares	16.24M shares	14640B shares
Shareholders Equity	$413.7M	$274.8M
YoY Change
Total Liabilities & Shareholders Equity	$2.577B	$2.512B
YoY Change	2.58%	8.46%

Cashflow Statement

Concept	2014 Q2	2013 Q2
OPERATING ACTIVITIES
Net Income	$83.10M	$165.2M
YoY Change	-49.7%	253.75%
Depreciation, Depletion And Amortization	$26.40M	$23.10M
YoY Change	14.29%	15.5%
Cash From Operating Activities	$128.0M	$105.4M
YoY Change	21.44%	-7.54%
INVESTING ACTIVITIES
Capital Expenditures	-$36.90M	-$42.70M
YoY Change	-13.58%	-29.19%
Acquisitions	$15.90M	$28.90M
YoY Change	-44.98%	1276.19%
Other Investing Activities	-$2.300M	-$10.80M
YoY Change	-78.7%	-320.41%
Cash From Investing Activities	-$39.20M	-$53.50M
YoY Change	-26.73%	-3.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-76.10M	-63.30M
YoY Change	20.22%	2.43%
NET CHANGE
Cash From Operating Activities	128.0M	105.4M
Cash From Investing Activities	-39.20M	-53.50M
Cash From Financing Activities	-76.10M	-63.30M
Net Change In Cash	12.70M	-11.40M
YoY Change	-211.4%	256.25%
FREE CASH FLOW
Cash From Operating Activities	$128.0M	$105.4M
Capital Expenditures	-$36.90M	-$42.70M
Free Cash Flow	$164.9M	$148.1M
YoY Change	11.34%	-15.03%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2849400000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12800000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14300000	USD
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	79400000	USD
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-18400000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	61900000	USD
CY2014Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	55700000	USD
CY2014Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	272300000	USD
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	261800000	USD
CY2014Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	100000	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-100000	USD
CY2014Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2841500000	USD
CY2013Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	23100000	USD
CY2014Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	24800000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1200000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	100000	shares
CY2013Q4	us-gaap	Assets Assets	2534400000	USD
CY2014Q2	us-gaap	Assets Assets	2576500000	USD
CY2014Q2	us-gaap	Assets Current AssetsCurrent	580900000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	580400000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-200000	USD
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2500000	shares
CY2014Q2	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	85000000	USD
CY2013Q2	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	166300000	USD
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	132700000	USD
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	218700000	USD
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	1159600000	USD
CY2013Q2	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	575700000	USD
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	1218900000	USD
CY2014Q2	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	616300000	USD
CY2014Q2	us-gaap	Business Combination Pro Forma Information Earnings Or Loss Of Acquiree Since Acquisition Date Actual BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual	1200000	USD
CY2014Q2	us-gaap	Business Combination Pro Forma Information Revenue Of Acquiree Since Acquisition Date Actual BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual	4500000	USD
CY2014Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets	91900000	USD
CY2014Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets	12100000	USD
CY2014Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities	7800000	USD
CY2014Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	70000000	USD
CY2014Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities	14100000	USD
CY2014Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	30400000	USD
	us-gaap	Business Combination Step Acquisition Equity Interest In Acquiree Fair Value1 BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1	-35000000	USD
	us-gaap	Business Combination Step Acquisition Equity Interest In Acquiree Fair Value1 BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1	0	USD
CY2013Q2	us-gaap	Business Combination Step Acquisition Equity Interest In Acquiree Fair Value1 BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1	0	USD
CY2014Q2	us-gaap	Business Combination Step Acquisition Equity Interest In Acquiree Fair Value1 BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1	-35000000	USD
	us-gaap	Business Combination Step Acquisition Equity Interest In Acquiree Remeasurement Gain BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain	27200000	USD
	us-gaap	Business Combination Step Acquisition Equity Interest In Acquiree Remeasurement Gain BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain	0	USD
CY2014Q2	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	5100000	USD
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	5100000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	64500000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	65800000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	132800000	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	68700000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-64100000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1300000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-1200000	USD
CY2004Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	10000000	shares
CY2014Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0	shares
CY2013Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2900000	shares
CY2014Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q1	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.18
CY2014Q2	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.18
	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.00
	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.36
CY2013Q2	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.00
CY2014Q2	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.18
CY2014Q2	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.18
CY2014Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.18
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	1.29
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2014Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2014Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	103970478	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	102648302	shares
CY2014Q2	us-gaap	Common Stock Value CommonStockValue	1000000	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	1000000	USD
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	83200000	USD
CY2013Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	163400000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	130000000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	214800000	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	29600000	USD
CY2013Q2	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	13800000	USD
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	28400000	USD
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	14800000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	159600000	USD
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	243200000	USD
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	98000000	USD
CY2013Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	177200000	USD
CY2014Q1	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	33.1455	shares
CY2014Q2	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	33.3222	shares
CY2014Q2	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	32.7869	shares
CY2014Q2	us-gaap	Costs And Expenses CostsAndExpenses	467500000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	934900000	USD
CY2013Q2	us-gaap	Costs And Expenses CostsAndExpenses	445900000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	890700000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-53500000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	62700000	USD
CY2014Q2	us-gaap	Deferred Tax Assets Liabilities Net Current DeferredTaxAssetsLiabilitiesNetCurrent	138900000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Liabilities Net Current DeferredTaxAssetsLiabilitiesNetCurrent	139000000	USD
CY2014Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	415000000	USD
CY2014Q2	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	138900000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	139000000	USD
CY2014Q2	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	276100000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	354300000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	6300000	USD
CY2014Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	30300000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	52800000	USD
CY2014Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	26400000	USD
CY2013Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	23100000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	45200000	USD
CY2014Q2	us-gaap	Derivative Assets Noncurrent DerivativeAssetsNoncurrent	6700000	USD
CY2014Q2	us-gaap	Derivative Gain On Derivative DerivativeGainOnDerivative	6700000	USD
	us-gaap	Derivative Gain On Derivative DerivativeGainOnDerivative	6700000	USD
	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	32000000	USD
	us-gaap	Dividends Preferred Stock DividendsPreferredStock	11500000	USD
CY2014Q2	us-gaap	Dividends Preferred Stock DividendsPreferredStock	1500000	USD
	us-gaap	Dividends Preferred Stock DividendsPreferredStock	3100000	USD
CY2013Q2	us-gaap	Dividends Preferred Stock DividendsPreferredStock	5800000	USD
	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	11500000	USD
	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	3100000	USD
CY2014Q2	us-gaap	Due From Related Parties Noncurrent DueFromRelatedPartiesNoncurrent	0	USD
CY2013Q4	us-gaap	Due From Related Parties Noncurrent DueFromRelatedPartiesNoncurrent	0	USD
CY2014Q2	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	0	USD
CY2013Q4	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	0	USD
CY2014Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.93
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.24
CY2013Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.82
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.44
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.33
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.09
CY2014Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.85
CY2013Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.66
CY2014Q2	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	11300000	USD
	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	5000000	USD
	us-gaap	Equity Method Investment Dividends Or Distributions EquityMethodInvestmentDividendsOrDistributions	6500000	USD
CY2013Q2	us-gaap	Equity Method Investment Summarized Financial Information Income Loss From Continuing Operations Before Extraordinary Items EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems	7300000	USD
CY2014Q2	us-gaap	Equity Method Investment Summarized Financial Information Income Loss From Continuing Operations Before Extraordinary Items EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems	5500000	USD
	us-gaap	Equity Method Investment Summarized Financial Information Income Loss From Continuing Operations Before Extraordinary Items EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems	24000000	USD
	us-gaap	Equity Method Investment Summarized Financial Information Income Loss From Continuing Operations Before Extraordinary Items EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems	14000000	USD
CY2013Q2	us-gaap	Equity Method Investment Summarized Financial Information Net Income Loss EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss	7300000	USD
CY2014Q2	us-gaap	Equity Method Investment Summarized Financial Information Net Income Loss EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss	5500000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-300000	USD
	us-gaap	Equity Method Investment Summarized Financial Information Net Income Loss EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss	24000000	USD
	us-gaap	Equity Method Investment Summarized Financial Information Net Income Loss EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss	14000000	USD
CY2014Q2	us-gaap	Equity Method Investment Summarized Financial Information Revenue EquityMethodInvestmentSummarizedFinancialInformationRevenue	15000000	USD
	us-gaap	Equity Method Investment Summarized Financial Information Revenue EquityMethodInvestmentSummarizedFinancialInformationRevenue	36300000	USD
CY2013Q2	us-gaap	Equity Method Investment Summarized Financial Information Revenue EquityMethodInvestmentSummarizedFinancialInformationRevenue	19700000	USD
	us-gaap	Equity Method Investment Summarized Financial Information Revenue EquityMethodInvestmentSummarizedFinancialInformationRevenue	39200000	USD
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	15600000	USD
CY2013Q2	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	15600000	USD
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	52000000	USD
CY2014Q2	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	52000000	USD
CY2014Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	30200000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	60900000	USD
CY2013Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	29500000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	59700000	USD
CY2014Q2	us-gaap	Goodwill Goodwill	491700000	USD
CY2013Q4	us-gaap	Goodwill Goodwill	456900000	USD
CY2014Q2	us-gaap	Goodwill Goodwill	34800000	USD
	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	34800000	USD
	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	13700000	USD
CY2013Q2	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	13700000	USD
CY2014Q2	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	34800000	USD
	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	1137100000	USD
CY2014Q2	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	604400000	USD
	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	1195600000	USD
CY2013Q2	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	564500000	USD
CY2014Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	79300000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	216800000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	126100000	USD
CY2013Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	165100000	USD
CY2014Q2	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	14800000	USD
	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	28400000	USD
CY2013Q2	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	13800000	USD
	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	29600000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	192200000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	225000000	USD
CY2014Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	130600000	USD
CY2013Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	92400000	USD
CY2014Q2	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	94100000	USD
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	245200000	USD
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	155700000	USD
CY2013Q2	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	178900000	USD
CY2014Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.89
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	2.24
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.40
CY2013Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.82
CY2014Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.81
CY2013Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	1.66
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	2.09
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-300000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	3700000	USD
CY2014Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	3800000	USD
CY2013Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	100000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	3700000	USD
CY2014Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	3800000	USD
CY2013Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	100000	USD
CY2013Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.00
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.04
CY2014Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.04
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.00
CY2014Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.04
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.00
CY2013Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.00
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.04
CY2014Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	2600000	USD
CY2013Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	3300000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	6200000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	6900000	USD
CY2014Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	36500000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	69300000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-53000000	USD
CY2013Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-86500000	USD
CY2014Q2	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	3000000	USD
	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	3000000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2700000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	9500000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	38800000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	35600000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	700000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-8400000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-20000000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-6200000	USD
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2013Q2	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	8100000	shares
CY2014Q2	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	8200000	shares
CY2014Q2	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	3200000	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	11600000	shares
CY2013Q2	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	11600000	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	3200000	shares
CY2014Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2500000	shares
CY2013Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2100000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1800000	shares
CY2013Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	88200000	USD
CY2014Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	103300000	USD
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	48600000	USD
CY2014Q2	us-gaap	Interest And Debt Expense InterestAndDebtExpense	27800000	USD
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	55700000	USD
CY2013Q2	us-gaap	Interest And Debt Expense InterestAndDebtExpense	24400000	USD
CY2014Q2	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	2300000	USD
	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	0	USD
CY2013Q2	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	0	USD
	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	4500000	USD
CY2013Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	20300000	USD
CY2014Q2	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	11000000	USD
CY2014Q2	us-gaap	Labor And Related Expense LaborAndRelatedExpense	285300000	USD
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	548200000	USD
CY2013Q2	us-gaap	Labor And Related Expense LaborAndRelatedExpense	273600000	USD
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	571400000	USD
CY2014Q2	us-gaap	Liabilities Liabilities	1915500000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	1959000000	USD
CY2014Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2576500000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2534400000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	311600000	USD
CY2014Q2	us-gaap	Liabilities Current LiabilitiesCurrent	299300000	USD
CY2013Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	1505200000	USD
CY2014Q2	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	1475100000	USD
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contingencies and Other Commitments</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We operate in a highly regulated and litigious industry. As a result, various lawsuits, claims, and legal and regulatory proceedings have been and can be expected to be instituted or asserted against us. The resolution of any such lawsuits, claims, or legal and regulatory proceedings could materially and adversely affect our financial position, results of operations, and cash flows in a given period. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Litigation By and Against Former Independent Auditor—</font></div><div style="line-height:120%;padding-bottom:13px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2003, claims on behalf of HealthSouth were brought against Ernst & Young, LLP in a stockholder derivative lawsuit initially filed in the Circuit Court of Jefferson County, Alabama on August 28, 2002 and captioned </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Tucker v. Scrushy</font><font style="font-family:inherit;font-size:10pt;">. The </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Tucker</font><font style="font-family:inherit;font-size:10pt;"> derivative litigation, including the claims against various other defendants and the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.9 billion</font><font style="font-family:inherit;font-size:10pt;"> judgment against Mr. Scrushy, our former chairman and chief executive officer, is more fully described in “Derivative Litigation” and “Litigation By and Against Former Independent Auditor” in Note 18, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Contingencies and Other Commitments</font><font style="font-family:inherit;font-size:10pt;">, to the consolidated financial statements accompanying the 2013 Form 10-K. The </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Tucker</font><font style="font-family:inherit;font-size:10pt;"> complaint alleges that from 1996 through 2002, when Ernst & Young served as our independent auditor, Ernst & Young acted recklessly and with gross negligence in performing its duties, and specifically that Ernst & Young failed to perform reviews and audits of our financial statements with due professional care as required by law and by its contractual agreements with us. The claims further allege Ernst & Young either knew of or, in the exercise of due care, should have discovered and investigated the fraudulent and improper accounting practices being directed by certain officers and employees, and should have reported them to our board of directors and the audit committee. The claims seek compensatory and punitive damages, disgorgement of fees received from us by Ernst & Young, and attorneys’ fees and costs. </font></div><div style="line-height:120%;padding-bottom:13px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 18, 2005, Ernst & Young filed a lawsuit captioned </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Ernst & Young LLP v. HealthSouth Corp.</font><font style="font-family:inherit;font-size:10pt;"> in the Circuit Court of Jefferson County, Alabama. The complaint alleges we provided Ernst & Young with fraudulent management representation letters, financial statements, invoices, bank reconciliations, and journal entries in an effort to conceal accounting fraud. Ernst & Young claims that as a result of our actions, Ernst & Young’s reputation has been injured and it has and will incur damages, expenses, and legal fees. On April 1, 2005, we answered Ernst & Young’s claims and asserted counterclaims related or identical to those asserted in the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Tucker</font><font style="font-family:inherit;font-size:10pt;"> action. Upon Ernst & Young’s motion, the Alabama state court referred Ernst & Young’s claims and our counterclaims to arbitration pursuant to a clause in the engagement agreements between HealthSouth and Ernst & Young. In August 2006, we and the derivative plaintiffs agreed to jointly prosecute the claims against Ernst & Young in arbitration.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The trial phase of the arbitration process began on July 12, 2010 before a three-person arbitration panel selected under rules of the American Arbitration Association (the “AAA”). On December 18, 2012, the AAA panel granted Ernst & Young’s motion to dismiss our claims on the grounds that HealthSouth is not permitted to pursue its claims since certain of its former officers and employees committed fraudulent acts. The panel also denied and dismissed Ernst & Young’s claims against us. On December 18, 2012, we, together with the stockholder derivative plaintiffs, filed a notice of appeal of the panel’s decision in the Circuit Court of Jefferson County, Alabama. On December 28, 2012, we filed a motion to vacate the decision. We assert that the panel’s decision is contrary to the Federal Arbitration Act and the duties of a public accounting firm to its corporate clients, and that the arbitrators exceeded their authority by entering an award contrary to Alabama law. On April 25, 2013, the court denied our motion to vacate. On June 4, 2013, we filed a notice of appeal to the Supreme Court of Alabama seeking review of the circuit court's denial of our motion to vacate the arbitration panel's decision. On June 13, 2014, the Supreme Court of Alabama affirmed the decision by the circuit court. On June 27, 2014, we filed an application for rehearing with the Supreme Court of Alabama. At this time, we do not know when the court will rule on that application.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on the ruling of the arbitration panel, we do not believe there is a reasonable possibility of a loss that might result from an adverse judgment or a settlement of this case.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">General Medicine Action—</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 16, 2004, General Medicine, P.C. filed a lawsuit against us captioned </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">General Medicine, P.C. v. HealthSouth Corp.</font><font style="font-family:inherit;font-size:10pt;"> seeking the recovery of allegedly fraudulent transfers involving assets of Horizon/CMS Healthcare Corporation, a former subsidiary of HealthSouth. The lawsuit is pending in the Circuit Court of Jefferson County, Alabama (the “Alabama Action”).</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General Medicine’s underlying claim against Horizon/CMS originates from a services contract entered into in 1995 between General Medicine and Horizon/CMS whereby General Medicine agreed to provide medical director services to skilled nursing facilities owned by Horizon/CMS for a term of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three years</font><font style="font-family:inherit;font-size:10pt;">. Horizon/CMS terminated the agreement for cause six months after it was executed, and General Medicine then initiated a lawsuit against Horizon/CMS in the United States District Court for the Eastern District of Michigan in 1996 (the “Michigan Action”). General Medicine’s complaint in the Michigan Action alleged that Horizon/CMS breached the services contract by wrongfully terminating General Medicine. We acquired Horizon/CMS in 1997 and sold it to Meadowbrook Healthcare, Inc. in 2001 pursuant to a stock purchase agreement. In 2004, Meadowbrook, without the knowledge of HealthSouth, consented to the entry of a final judgment in the Michigan Action in favor of General Medicine against Horizon/CMS for the alleged wrongful termination of the contract with General Medicine in the amount of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$376 million</font><font style="font-family:inherit;font-size:10pt;">, plus interest from the date of the judgment until paid at the rate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">10%</font><font style="font-family:inherit;font-size:10pt;"> per annum (the “Consent Judgment”). The </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$376 million</font><font style="font-family:inherit;font-size:10pt;"> damages figure was unilaterally selected by General Medicine and was not tested or opposed by Meadowbrook. Additionally, the settlement agreement (the “Settlement”) used as the basis for the Consent Judgment provided that Meadowbrook would pay only </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$300,000</font><font style="font-family:inherit;font-size:10pt;"> to General Medicine to settle the Michigan Action and that General Medicine would seek to recover the remaining balance of the Consent Judgment solely from us. We were not a party to the Michigan Action, the Settlement negotiated by Meadowbrook, or the Consent Judgment. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The complaint filed by General Medicine against us in the Alabama Action alleges that while Horizon/CMS was our wholly owned subsidiary, General Medicine was an existing creditor of Horizon/CMS by virtue of the breach of contract claim underlying the Settlement. The complaint also alleges we caused Horizon/CMS to transfer its assets to us for less than a reasonably equivalent value or, in the alternative, with the actual intent to defraud creditors of Horizon/CMS, including General Medicine, in violation of the Alabama Uniform Fraudulent Transfer Act. General Medicine further alleges in its amended complaint that we are liable for the Consent Judgment despite not being a party to it because as Horizon/CMS’s parent we failed to observe corporate formalities in our operation and ownership of Horizon/CMS, misused our control of Horizon/CMS, stripped assets from Horizon/CMS, and engaged in other conduct which amounted to a fraud on Horizon/CMS’s creditors. General Medicine has requested relief including recovery of the unpaid amount of the Consent Judgment, the avoidance of the subject transfers of assets, attachment of the assets transferred to us, appointment of a receiver over the transferred properties, and a monetary judgment for the value of properties transferred. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have denied liability to General Medicine and asserted defenses and counterclaims against General Medicine for fraud, tortious interference with business relations, conspiracy, abuse of process, and other causes of action. In our counterclaims, we alleged the Consent Judgment is the product of fraud and collusion by General Medicine and Meadowbrook and, further, that these parties were guilty of a conspiracy to manufacture a lawsuit against HealthSouth in favor of General Medicine. Consequently, we assert that the Consent Judgment is not evidence of a legitimate debt owed by Horizon/CMS to General Medicine that is collectible from HealthSouth under any theory of liability.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2008, after we obtained discovery concerning the circumstances that led to the entry of the Consent Judgment, we filed a motion in the Michigan Action asking the court to set aside the Consent Judgment on grounds that it was the product of fraud on the court and collusion by the parties. On May 21, 2009, the court granted our motion to set aside the Consent Judgment on grounds that it was the product of fraud on the court. On March 9, 2010, General Medicine filed an appeal of the court's decision to the Sixth Circuit Court of Appeals. The parties agreed to a voluntary stay of the Alabama Action pending the outcome of General Medicine's appeal to the Sixth Circuit Court of Appeals. On April 10, 2012, the Sixth Circuit Court of Appeals reversed the lower court's ruling and reinstated the Consent Judgment. Due to the conclusion of the appeal in the Michigan Action, General Medicine requested reactivation of the Alabama Action in the Circuit Court of Jefferson County, Alabama. On January 10, 2013, we filed a motion for partial summary judgment in the Alabama Action seeking a declaration that the Consent Judgment obtained by General Medicine is not enforceable against us because, among other reasons, it was the result of collusion. On February 27, 2013, the court denied our motion. The court also indicated it concurred with the Sixth Circuit Court of Appeals that the Consent Judgment did nothing more than establish Horizon/CMS's liability to General Medicine and did not establish the amount of General Medicine’s damages claim against Horizon/CMS or the merits of General Medicine's separate fraudulent conveyance claims against HealthSouth.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 9, 2014 and on February 18, 2014, the court in the Alabama Action entered rulings which together provided that the </font><font style="font-family:inherit;font-size:10pt;">$376 million</font><font style="font-family:inherit;font-size:10pt;"> damages figure contained in the Consent Judgment is not admissible at trial and that the issue of collusion with respect to the amount of the Consent Judgment is now moot. Instead of relying on the Consent Judgment to prove damages against Horizon/CMS, General Medicine will be required to prove the amount of any damages it has against Horizon/CMS. On March 31, 2014, General Medicine filed a motion seeking partial summary judgment and requesting dismissal of our defenses and counterclaims which allege the Consent Judgment was the product of fraud and collusion. On July 15, 2014, the court issued an order denying General Medicine’s motion for partial summary judgment. Accordingly, at trial we will be permitted to present our defenses and counterclaims of fraud and collusion against General Medicine.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 3, 2014, the Consent Judgment expired under applicable Michigan law without renewal by General Medicine. Based on the expiration, on July 23, 2014, we filed a motion for summary judgment requesting dismissal of General Medicine’s lawsuit against us on grounds that General Medicine is no longer a “creditor” of Horizon/CMS, which is an essential element of the fraudulent transfer and alter ego claims against us. On August 7, 2014, the court will hear our motion, as well as General Medicine’s motion for partial summary judgment arguing that the Consent Judgment has not expired and that it remains a valid basis for a fraudulent transfer claim. The Alabama Action is set for trial beginning on September 15, 2014.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We intend to vigorously defend ourselves against General Medicine’s claims and to vigorously prosecute our counterclaims for fraud and collusion against General Medicine. Based on the stage of litigation, review of the current facts and circumstances as we understand them, the nature of the underlying claim, the results of the proceedings to date, and the nature and scope of the defense we continue to mount, we do not believe an adverse judgment or settlement is probable in this matter, and it is also not possible to estimate the amount of loss, if any, or range of possible loss that might result from an adverse judgment or settlement of this case.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Litigation—</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have been named as a defendant in a lawsuit filed March 28, 2003 by several individual stockholders in the Circuit Court of Jefferson County, Alabama, captioned </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Nichols v. HealthSouth Corp</font><font style="font-family:inherit;font-size:10pt;">. The plaintiffs allege that we, some of our former officers, and our former investment bank engaged in a scheme to overstate and misrepresent our earnings and financial position. The plaintiffs are seeking compensatory and punitive damages. This case was consolidated with the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Tucker</font><font style="font-family:inherit;font-size:10pt;"> case for discovery and other pretrial purposes and was stayed in the Circuit Court on August 8, 2005. The plaintiffs filed an amended complaint on November 9, 2010 to which we responded with a motion to dismiss filed on December 22, 2010. During a hearing on February 24, 2012, plaintiffs’ counsel indicated his intent to dismiss certain claims against us. Instead, on March 9, 2012, the plaintiffs amended their complaint to include additional securities fraud claims against HealthSouth and add several former officers to the lawsuit. On September 12, 2012, the plaintiffs further amended their complaint to request certification as a class action. One of those named officers has repeatedly attempted to remove the case to federal district court, most recently on December 11, 2012. We filed our latest motion to remand the case back to state court on January 10, 2013. On September 27, 2013, the federal court remanded the case back to state court. We intend to vigorously defend ourselves in this case. Based on the stage of litigation, review of the current facts and circumstances as we understand them, the nature of the underlying claim, the results of the proceedings to date, and the nature and scope of the defense we continue to mount, we do not believe an adverse judgment or settlement is probable in this matter, and it is also not possible to estimate the amount of loss, if any, or range of possible loss that might result from an adverse judgment or settlement of this case.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Governmental Inquiries and Investigations—</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 24, 2011, we received a document subpoena addressed to HealthSouth Hospital of Houston, a long-term acute care hospital (“LTCH”) we closed in August 2011, and issued from the Dallas, Texas office of the U.S. Department of Health and Human Services, Office of the Inspector General (the “HHS-OIG”). The subpoena stated it was in connection with an investigation of possible false or otherwise improper claims submitted to Medicare and Medicaid and requested documents and materials relating to patient admissions, length of stay, and discharge matters at this closed LTCH. We furnished the documents requested and have heard nothing from HHS-OIG since December 2012.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 4, 2013, we received document subpoenas from an office of the HHS-OIG addressed to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">four</font><font style="font-family:inherit;font-size:10pt;"> of our hospitals. Those subpoenas also requested complete copies of medical records for </font><font style="font-family:inherit;font-size:10pt;">100</font><font style="font-family:inherit;font-size:10pt;"> patients treated at each of those hospitals between September 2008 and June 2012. The investigation is being conducted by the United States Department of Justice (the “DOJ”). On April 24, 2014, we received document subpoenas relating to an additional </font><font style="font-family:inherit;font-size:10pt;">seven</font><font style="font-family:inherit;font-size:10pt;"> of our hospitals. The new subpoenas reference substantially similar investigation subject matter as the original subpoenas and request materials from the period January 2008 through December 2013. Two of the four hospitals addressed in the original set of subpoenas have received supplemental subpoenas to cover this new time period. The new subpoenas do not include requests for specific patient files, but it is expected that such requests will be made for the new group of hospitals. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All of the subpoenas are in connection with an investigation of alleged improper or fraudulent claims submitted to Medicare and Medicaid and requests documents and materials relating to practices, procedures, protocols and policies, of certain pre- and post-admissions activities at these hospitals including, among other things, marketing functions, pre-admission screening, post-admission physician evaluations, patient assessment instruments, individualized patient plans of care, and compliance with the Medicare </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">60%</font><font style="font-family:inherit;font-size:10pt;"> rule. Under the Medicare rule commonly referred to as the “</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">60%</font><font style="font-family:inherit;font-size:10pt;"> rule,” an inpatient rehabilitation hospital must treat </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">60%</font><font style="font-family:inherit;font-size:10pt;"> or more of its patients from at least one of a specified list of medical conditions in order to be reimbursed at the inpatient rehabilitation hospital payment rates, rather than at the lower acute care hospital payment rates. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are cooperating fully with the DOJ in connection with these subpoenas and are currently unable to predict the timing or outcome of the related investigations. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Matters—</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The False Claims Act, 18 U.S.C. § 287, allows private citizens, called “relators,” to institute civil proceedings alleging violations of the False Claims Act. These </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> cases are generally sealed by the court at the time of filing. The only parties typically privy to the information contained in the complaint are the relator, the federal government, and the presiding court. It is possible that </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> lawsuits have been filed against us and that those suits remain under seal or that we are unaware of such filings or prevented by existing law or court order from discussing or disclosing the filing of such suits. We may be subject to liability under one or more undisclosed </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</font><font style="font-family:inherit;font-size:10pt;"> cases brought pursuant to the False Claims Act.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It is our obligation as a participant in Medicare and other federal healthcare programs to routinely conduct audits and reviews of the accuracy of our billing systems and other regulatory compliance matters. As a result of these reviews, we have made, and will continue to make, disclosures to the HHS-OIG and the United States Centers for Medicare and Medicaid Services relating to amounts we suspect represent over-payments from these programs, whether due to inaccurate billing or otherwise. Some of these disclosures have resulted in, or may result in, HealthSouth refunding amounts to Medicare or other federal healthcare programs.</font></div></div>
	us-gaap	Management Fees Revenue ManagementFeesRevenue	0	USD
CY2014Q2	us-gaap	Management Fees Revenue ManagementFeesRevenue	0	USD
CY2013Q2	us-gaap	Management Fees Revenue ManagementFeesRevenue	0	USD
	us-gaap	Management Fees Revenue ManagementFeesRevenue	0	USD
CY2013Q4	us-gaap	Minority Interest MinorityInterest	124100000	USD
CY2014Q2	us-gaap	Minority Interest MinorityInterest	141700000	USD
	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	20400000	USD
	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	22300000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-126800000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-189500000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-101400000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-107000000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	235100000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	226800000	USD
	us-gaap	Net Income Loss NetIncomeLoss	216500000	USD
	us-gaap	Net Income Loss NetIncomeLoss	129800000	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	165200000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	83100000	USD
CY2013Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	13800000	USD
CY2014Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	14800000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	28400000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	29600000	USD
	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	25800000	USD
CY2014Q2	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	13200000	USD
	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	26000000	USD
CY2013Q2	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	12500000	USD
CY2013Q2	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	1300000	USD
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	3600000	USD
CY2014Q2	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	1600000	USD
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	2600000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	205000000	USD
CY2013Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	159400000	USD
CY2014Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	81600000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	126700000	USD
CY2013Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	165200000	USD
CY2014Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	85400000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	134300000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	216500000	USD
CY2014Q2	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	-21900000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	-21900000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	-400000	USD
CY2013Q2	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	-400000	USD
	us-gaap	Noncontrolling Interest Increase From Business Combination NoncontrollingInterestIncreaseFromBusinessCombination	14000000	USD
CY2014Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	761000000	USD
CY2013Q4	us-gaap	Other Assets Current OtherAssetsCurrent	115100000	USD
CY2014Q2	us-gaap	Other Assets Current OtherAssetsCurrent	103900000	USD
CY2014Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	148000000	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	144100000	USD
	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	-1800000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	100000	USD
CY2013Q2	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	-1900000	USD
	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	200000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	200000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	100000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1700000	USD
CY2013Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1800000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	500000	USD
CY2013Q2	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	1000000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	500000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	1000000	USD
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	USD
	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-100000	USD
CY2013Q2	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-100000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-800000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	700000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	600000	USD
CY2013Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-900000	USD
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	159100000	USD
CY2013Q2	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	81000000	USD
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	170800000	USD
CY2014Q2	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	86300000	USD
CY2013Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	249700000	USD
CY2014Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	243600000	USD
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	142200000	USD
CY2014Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	141100000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-300000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-6100000	USD
CY2013Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1900000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2600000	USD
CY2014Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	28200000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	29900000	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-8400000	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-9400000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	234100000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	43100000	USD
	us-gaap	Payments For Software PaymentsForSoftware	11900000	USD
	us-gaap	Payments For Software PaymentsForSoftware	11000000	USD
	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	0	USD
	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	31600000	USD
	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	25400000	USD
	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	23900000	USD
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	3100000	USD
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	11500000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	28900000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	15900000	USD
CY2013Q2	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	28900000	USD
CY2014Q2	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	15900000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	89500000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	69000000	USD
	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	132000000	USD
	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	65000000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	7000000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	6400000	USD
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	0	USD
	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	0	USD
	us-gaap	Profit Loss ProfitLoss	244900000	USD
	us-gaap	Profit Loss ProfitLoss	159400000	USD
CY2013Q2	us-gaap	Profit Loss ProfitLoss	179000000	USD
CY2014Q2	us-gaap	Profit Loss ProfitLoss	97900000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	910500000	USD
CY2014Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	976500000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	14400000	USD
CY2013Q2	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	7000000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	16800000	USD
CY2014Q2	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	9300000	USD
CY2014Q2	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	12400000	USD
CY2013Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	13500000	USD
	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	59000000	USD
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	95000000	USD
CY2014Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1971300000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2101100000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	14300000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	12800000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	4000000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	6300000	USD
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	413700000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	344600000	USD
CY2014Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	555400000	USD
CY2013Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	468700000	USD
CY2013Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	392700000	USD
CY2012Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	403500000	USD
	us-gaap	Stockholders Equity Other StockholdersEquityOther	-1900000	USD
	us-gaap	Stockholders Equity Other StockholdersEquityOther	-200000	USD
CY2014Q2	us-gaap	Supplies Expense SuppliesExpense	27800000	USD
CY2013Q2	us-gaap	Supplies Expense SuppliesExpense	26600000	USD
	us-gaap	Supplies Expense SuppliesExpense	52800000	USD
	us-gaap	Supplies Expense SuppliesExpense	55400000	USD
CY2014Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	93200000	USD
CY2013Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	93200000	USD
CY2014Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	16243774	shares
CY2013Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	14654436	shares
CY2014Q2	us-gaap	Treasury Stock Value TreasuryStockValue	457600000	USD
CY2013Q4	us-gaap	Treasury Stock Value TreasuryStockValue	404600000	USD
CY2013Q2	us-gaap	Undistributed Earnings Allocated To Participating Securities UndistributedEarningsAllocatedToParticipatingSecurities	-2900000	USD
CY2014Q2	us-gaap	Undistributed Earnings Allocated To Participating Securities UndistributedEarningsAllocatedToParticipatingSecurities	-1100000	USD
	us-gaap	Undistributed Earnings Allocated To Participating Securities UndistributedEarningsAllocatedToParticipatingSecurities	-3500000	USD
	us-gaap	Undistributed Earnings Allocated To Participating Securities UndistributedEarningsAllocatedToParticipatingSecurities	-1600000	USD
CY2013Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1100000	USD
CY2014Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	400000	USD
	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	700000	USD
CY2013Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	300000	USD
	hls	Percentage Of Net Operating Revenues Medicaid PercentageOfNetOperatingRevenuesMedicaid	0.015
CY2014Q2	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	100000	USD
CY2014Q2	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0	USD
CY2014Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	100600000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	100800000	shares
CY2013Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	99800000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	103400000	shares
CY2013Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	86100000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	90000000	shares
CY2014Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	86700000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	87000000	shares
	hls	Business Combination Acquisition Of Less Than100 Percent Noncontrolling Interest Fair Value Of Equity Interest BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValueOfEquityInterest	-14000000	USD
	hls	Business Combination Acquisition Of Less Than100 Percent Noncontrolling Interest Fair Value Of Equity Interest BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValueOfEquityInterest	0	USD
CY2014Q2	hls	Business Combination Acquisition Of Less Than100 Percent Noncontrolling Interest Fair Value Of Equity Interest BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValueOfEquityInterest	-14000000	USD
CY2013Q2	hls	Business Combination Acquisition Of Less Than100 Percent Noncontrolling Interest Fair Value Of Equity Interest BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValueOfEquityInterest	0	USD
CY2013Q4	hls	Classof Warrant Exercise Priceof Warrants ClassofWarrantExercisePriceofWarrants	32.50
CY2014Q2	hls	Consolidatedcoverageratiominimum Consolidatedcoverageratiominimum	2
CY2014Q1	hls	Convertible Preferred Stock Conversion Price ConvertiblePreferredStockConversionPrice	30.17
CY2014Q2	hls	Convertible Preferred Stock Conversion Price ConvertiblePreferredStockConversionPrice	30.01
CY2014Q2	hls	Convertible Preferred Stock Conversion Price ConvertiblePreferredStockConversionPrice	30.50
	hls	Equity In Net Income Of Consolidated Affiliates EquityInNetIncomeOfConsolidatedAffiliates	0	USD
CY2014Q2	hls	Equity In Net Income Of Consolidated Affiliates EquityInNetIncomeOfConsolidatedAffiliates	0	USD
CY2013Q2	hls	Equity In Net Income Of Consolidated Affiliates EquityInNetIncomeOfConsolidatedAffiliates	0	USD
	hls	Equity In Net Income Of Consolidated Affiliates EquityInNetIncomeOfConsolidatedAffiliates	0	USD
	hls	Equity Method Investment Summarized Financial Information Operating Expenses EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses	-19400000	USD
	hls	Equity Method Investment Summarized Financial Information Operating Expenses EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses	-22200000	USD
CY2013Q2	hls	Equity Method Investment Summarized Financial Information Operating Expenses EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses	-11000000	USD
CY2014Q2	hls	Equity Method Investment Summarized Financial Information Operating Expenses EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses	-8200000	USD
CY2014Q1	hls	Expirationof Warrants ExpirationofWarrants	100000	shares
CY2014Q2	hls	Government Class Action And Related Settlements Gain Loss GovernmentClassActionAndRelatedSettlementsGainLoss	-800000	USD
	hls	Government Class Action And Related Settlements Gain Loss GovernmentClassActionAndRelatedSettlementsGainLoss	-800000	USD
CY2013Q2	hls	Government Class Action And Related Settlements Gain Loss GovernmentClassActionAndRelatedSettlementsGainLoss	-2000000	USD
	hls	Government Class Action And Related Settlements Gain Loss GovernmentClassActionAndRelatedSettlementsGainLoss	-2000000	USD
	hls	Income Loss From Continuing Operations Attributable To Common Shareholders Basic IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic	121400000	USD
	hls	Income Loss From Continuing Operations Attributable To Common Shareholders Basic IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic	201800000	USD
CY2014Q2	hls	Income Loss From Continuing Operations Attributable To Common Shareholders Basic IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic	76700000	USD
CY2013Q2	hls	Income Loss From Continuing Operations Attributable To Common Shareholders Basic IncomeLossFromContinuingOperationsAttributableToCommonShareholdersBasic	156400000	USD
CY2013Q2	hls	Income Loss From Continuing Operations Attributable To Common Shareholders Diluted IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted	165100000	USD
	hls	Income Loss From Continuing Operations Attributable To Common Shareholders Diluted IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted	216800000	USD
CY2014Q2	hls	Income Loss From Continuing Operations Attributable To Common Shareholders Diluted IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted	81600000	USD
	hls	Income Loss From Continuing Operations Attributable To Common Shareholders Diluted IncomeLossFromContinuingOperationsAttributableToCommonShareholdersDiluted	130600000	USD
	hls	Net Income Loss Availableto Common Stockholders NetIncomeLossAvailabletoCommonStockholders	125000000	USD
CY2013Q2	hls	Net Income Loss Availableto Common Stockholders NetIncomeLossAvailabletoCommonStockholders	156500000	USD
CY2014Q2	hls	Net Income Loss Availableto Common Stockholders NetIncomeLossAvailabletoCommonStockholders	80400000	USD
	hls	Net Income Loss Availableto Common Stockholders NetIncomeLossAvailabletoCommonStockholders	201500000	USD
	hls	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest Total NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterestTotal	242300000	USD
	hls	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest Total NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterestTotal	155800000	USD
	hls	Net Operating Revenues Less Provision For Doubtful Accounts NetOperatingRevenuesLessProvisionForDoubtfulAccounts	1122700000	USD
CY2014Q2	hls	Net Operating Revenues Less Provision For Doubtful Accounts NetOperatingRevenuesLessProvisionForDoubtfulAccounts	595100000	USD
CY2013Q2	hls	Net Operating Revenues Less Provision For Doubtful Accounts NetOperatingRevenuesLessProvisionForDoubtfulAccounts	557500000	USD
	hls	Net Operating Revenues Less Provision For Doubtful Accounts NetOperatingRevenuesLessProvisionForDoubtfulAccounts	1178800000	USD
CY2014Q2	hls	Number Of General Or Limited Partnerships Limited Liability Companies Or Joint Ventures NumberOfGeneralOrLimitedPartnershipsLimitedLiabilityCompaniesOrJointVentures	8	facilities
CY2014Q2	hls	Number Of Partially Owned Subsidiaries Nonconsolidated NumberOfPartiallyOwnedSubsidiariesNonconsolidated	9	facilities
	hls	Occupancy Cost OccupancyCost	20800000	USD
CY2014Q2	hls	Occupancy Cost OccupancyCost	10300000	USD
CY2013Q2	hls	Occupancy Cost OccupancyCost	11900000	USD
	hls	Occupancy Cost OccupancyCost	24100000	USD
CY2007Q4	hls	Option Contract Annual Premium OptionContractAnnualPremium	0.15
CY2007Q4	hls	Option Contract Exercisable OptionContractExercisable	0.30
	hls	Ownership Percentage Of Subsidiary Guarantors OwnershipPercentageOfSubsidiaryGuarantors	1.00
	hls	Percentage Of Net Operating Revenues Medicaid PercentageOfNetOperatingRevenuesMedicaid	0.011
CY2013Q2	hls	Percentage Of Net Operating Revenues Managed Care PercentageOfNetOperatingRevenuesManagedCare	0.184
	hls	Percentage Of Net Operating Revenues Managed Care PercentageOfNetOperatingRevenuesManagedCare	0.184
	hls	Percentage Of Net Operating Revenues Managed Care PercentageOfNetOperatingRevenuesManagedCare	0.184
CY2014Q2	hls	Percentage Of Net Operating Revenues Managed Care PercentageOfNetOperatingRevenuesManagedCare	0.187
CY2013Q2	hls	Percentage Of Net Operating Revenues Medicaid PercentageOfNetOperatingRevenuesMedicaid	0.010
CY2014Q2	hls	Percentage Of Net Operating Revenues Medicaid PercentageOfNetOperatingRevenuesMedicaid	0.018
CY2014Q2	hls	Percentage Of Net Operating Revenues Medicare PercentageOfNetOperatingRevenuesMedicare	0.741
CY2013Q2	hls	Percentage Of Net Operating Revenues Medicare PercentageOfNetOperatingRevenuesMedicare	0.746
	hls	Percentage Of Net Operating Revenues Medicare PercentageOfNetOperatingRevenuesMedicare	0.746
	hls	Percentage Of Net Operating Revenues Medicare PercentageOfNetOperatingRevenuesMedicare	0.747
CY2013Q2	hls	Percentage Of Net Operating Revenues Other Income PercentageOfNetOperatingRevenuesOtherIncome	0.019
CY2014Q2	hls	Percentage Of Net Operating Revenues Other Income PercentageOfNetOperatingRevenuesOtherIncome	0.016
	hls	Percentage Of Net Operating Revenues Other Income PercentageOfNetOperatingRevenuesOtherIncome	0.017
	hls	Percentage Of Net Operating Revenues Other Income PercentageOfNetOperatingRevenuesOtherIncome	0.016
	hls	Percentage Of Net Operating Revenues Other Third Party Payors PercentageOfNetOperatingRevenuesOtherThirdPartyPayors	0.016
	hls	Percentage Of Net Operating Revenues Other Third Party Payors PercentageOfNetOperatingRevenuesOtherThirdPartyPayors	0.017
CY2014Q2	hls	Percentage Of Net Operating Revenues Other Third Party Payors PercentageOfNetOperatingRevenuesOtherThirdPartyPayors	0.017
CY2013Q2	hls	Percentage Of Net Operating Revenues Other Third Party Payors PercentageOfNetOperatingRevenuesOtherThirdPartyPayors	0.017
CY2014Q2	hls	Percentage Of Net Operating Revenues Patients PercentageOfNetOperatingRevenuesPatients	0.009
	hls	Percentage Of Net Operating Revenues Patients PercentageOfNetOperatingRevenuesPatients	0.012
CY2013Q2	hls	Percentage Of Net Operating Revenues Patients PercentageOfNetOperatingRevenuesPatients	0.012
	hls	Percentage Of Net Operating Revenues Patients PercentageOfNetOperatingRevenuesPatients	0.010
CY2014Q2	hls	Percentage Of Net Operating Revenues Total PercentageOfNetOperatingRevenuesTotal	1.000
	hls	Percentage Of Net Operating Revenues Total PercentageOfNetOperatingRevenuesTotal	1.000
CY2013Q2	hls	Percentage Of Net Operating Revenues Total PercentageOfNetOperatingRevenuesTotal	1.000
	hls	Percentage Of Net Operating Revenues Total PercentageOfNetOperatingRevenuesTotal	1.000
	hls	Percentage Of Net Operating Revenues Workers Compensation PercentageOfNetOperatingRevenuesWorkersCompensation	0.013
CY2013Q2	hls	Percentage Of Net Operating Revenues Workers Compensation PercentageOfNetOperatingRevenuesWorkersCompensation	0.012
CY2014Q2	hls	Percentage Of Net Operating Revenues Workers Compensation PercentageOfNetOperatingRevenuesWorkersCompensation	0.012
	hls	Percentage Of Net Operating Revenues Workers Compensation PercentageOfNetOperatingRevenuesWorkersCompensation	0.012
CY2013Q2	hls	Professional Fees Accounting Tax And Legal ProfessionalFeesAccountingTaxAndLegal	2200000	USD
	hls	Professional Fees Accounting Tax And Legal ProfessionalFeesAccountingTaxAndLegal	3600000	USD
	hls	Professional Fees Accounting Tax And Legal ProfessionalFeesAccountingTaxAndLegal	3600000	USD
CY2014Q2	hls	Professional Fees Accounting Tax And Legal ProfessionalFeesAccountingTaxAndLegal	2000000	USD
CY2014Q2	hls	Seniorsecuredleverageratiomaximum Seniorsecuredleverageratiomaximum	1.5
	hls	Treasury Stock Reacquired TreasuryStockReacquired	5800000	USD
	hls	Treasury Stock Reacquired TreasuryStockReacquired	9700000	USD
	hls	Treasury Stock Value Acquired Cost Method Common Stock TreasuryStockValueAcquiredCostMethodCommonStock	234100000	USD
	hls	Treasury Stock Value Acquired Cost Method Common Stock TreasuryStockValueAcquiredCostMethodCommonStock	43100000	USD
	hls	Undistributed Earnings From Discontinued Operations Allocatedto Participating Securities UndistributedEarningsFromDiscontinuedOperationsAllocatedtoParticipatingSecurities	-100000	USD
	hls	Undistributed Earnings From Discontinued Operations Allocatedto Participating Securities UndistributedEarningsFromDiscontinuedOperationsAllocatedtoParticipatingSecurities	0	USD
CY2014Q2	hls	Undistributed Earnings From Discontinued Operations Allocatedto Participating Securities UndistributedEarningsFromDiscontinuedOperationsAllocatedtoParticipatingSecurities	-100000	USD
CY2013Q2	hls	Undistributed Earnings From Discontinued Operations Allocatedto Participating Securities UndistributedEarningsFromDiscontinuedOperationsAllocatedtoParticipatingSecurities	0	USD
	hls	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedDecreasesResultingFromPriorPeriodTaxPositions	300000	USD
	hls	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccruedIncreasesResultingFromPriorPeriodTaxPositions	100000	USD
	hls	Warrants Exercised Value WarrantsExercisedValue	6300000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	dei	Document Period End Date DocumentPeriodEndDate	2014-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0000785161
CY2014Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	87726340	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2013Q2	dei	Entity Public Float EntityPublicFloat	2500000000	USD
	dei	Entity Registrant Name EntityRegistrantName	HEALTHSOUTH CORP
	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes

Files In Submission

Name	View Source	Status
0000785161-14-000043-index-headers.html	Edgar Link	pending
0000785161-14-000043-index.html	Edgar Link	pending
0000785161-14-000043.txt	Edgar Link	pending
0000785161-14-000043-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
hls-20140630.xml	Edgar Link	completed
hls-20140630.xsd	Edgar Link	pending
hls-20140630_cal.xml	Edgar Link	unprocessable
hls-20140630_def.xml	Edgar Link	unprocessable
hls-20140630_lab.xml	Edgar Link	unprocessable
hls-20140630_pre.xml	Edgar Link	unprocessable
hls10q63014.htm	Edgar Link	pending
hls10q63014ex101.htm	Edgar Link	pending
hls10q63014ex311.htm	Edgar Link	pending
hls10q63014ex312.htm	Edgar Link	pending
hls10q63014ex321.htm	Edgar Link	pending
hls10q63014ex322.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EHC
Encompass Health Corp Stock $ehc

2014 Q2 Form 10-Q Financial Statement

#000078516114000043 Filed on July 29, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EHC Encompass Health Corp Stock $ehc

2014 Q2 Form 10-Q Financial Statement

#000078516114000043 Filed on July 29, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EHC
Encompass Health Corp Stock $ehc